Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") announced that VEOZAtm (fezolinetant)*, its first-in-class treatment for moderate to severe vasomotor symptoms (VMS) ...
Some results have been hidden because they may be inaccessible to you